FOXO4-DRI
FOXO4-DRI is a longevity peptide used in evidence-based, physician-supervised protocols. Use as senolytic cycle for longevity, immune rejuvenation, and chronic inflammation driven by senescent cells.
What is FOXO4-DRI?
FOXO4-p53 interaction disruptor. Blocks FOXO4 from sequestering p53 in senescent cells, freeing p53 to activate apoptosis in senescent cells only. Targeted senolytic — does not kill healthy cells. Clears senescent cell burden. IMPORTANT: Not for continuous use — cycles only (2-3 days every 1-3 months).
Uses & clinical decision logic
Use as senolytic cycle for longevity, immune rejuvenation, and chronic inflammation driven by senescent cells. Dose: 5mg on cycle days.
FOXO4-DRI dosage & administration
| Vial size | BAC water | Dosing range | Units / dose | Frequency | Route |
|---|---|---|---|---|---|
| 10mg | 2mL | 5mg | 100 units | 2-3 days per cycle, every 1-3 months | SubQ |
Safety & contraindications
Do not use continuously — chronic FOXO4-p53 disruption in healthy cells may be harmful. Not for cancer patients (senescent tumor suppression mechanism).
Stacking & combinations
Sequence after Epithalon/MOTS-c cycle for cellular rejuvenation cascade.
Related peptides
Frequently asked questions
What is FOXO4-DRI used for?
Use as senolytic cycle for longevity, immune rejuvenation, and chronic inflammation driven by senescent cells. Dose: 5mg on cycle days.
What is the typical FOXO4-DRI dosage?
Common dosing ranges from 5mg (2-3 days per cycle, every 1-3 months, SubQ). Exact dosing is individualized and set by a licensed physician.
How is FOXO4-DRI administered?
FOXO4-DRI is typically administered via SubQ.
What are the contraindications for FOXO4-DRI?
Do not use continuously — chronic FOXO4-p53 disruption in healthy cells may be harmful. Not for cancer patients (senescent tumor suppression mechanism).
Build a physician-supervised protocol around your goal — no gatekeeping, real doctors, 503A compounding pharmacies.
Build your protocol →This page is for educational purposes only and is not medical advice. Peptide therapies described here are provided under physician supervision through 503A compounding pharmacies. Many peptides are not FDA-approved for the uses described. Do not start, stop, or change any protocol without consulting a licensed physician.